XCUR — EXICURE, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1698530 ·
Last close
$2.67
Market Cap
$17.04M
52W High
$5.07
52W Low
$2.63
ADV30
15,956
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -2,256,000 | -2,898,000 | 14,041,000 | 3,746,000 | 10,115,000 |
| Sep 2025 | 0 | — | -2,387,000 | -2,437,000 | 15,267,000 | 4,438,000 | 8,340,000 |
| Jun 2025 | 0 | — | -2,449,000 | -2,621,000 | 18,738,000 | 7,858,000 | 9,875,000 |
| Mar 2025 | 0 | — | -3,025,000 | 3,010,000 | 20,680,000 | 10,420,000 | 9,298,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,555,000
Investing CF
$-1,807,000
Financing CF
$1,600,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.88
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-204,210,000
Inventory
—
Receivables
$58,000
ST Investments
—
EBIT TTM
$-11,442,000
Pretax Income TTM
$-5,580,000
Interest Exp TTM
$13,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,117,000 | -4,946,000 | 14,041,000 | 10,115,000 | — | -8,555,000 |
| Dec 2024 | 500,000 | -4,949,000 | -9,701,000 | 15,056,000 | 8,284,000 | — | -2,910,000 |
| Dec 2023 | 0 | -13,138,000 | -16,914,000 | 11,580,000 | 8,549,000 | — | -10,357,000 |
| Dec 2022 | 28,826,000 | -1,831,000 | -2,582,000 | 23,328,000 | 8,406,000 | — | -35,658,000 |
TTM Snapshot
Revenues TTM
$-1,661,000
NetIncome TTM
$-35,038,000
OpCashFlow TTM
$0
Assets (Latest)
$15,056,000
Forward EPS
$-0.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NCEL | NewcelX Ltd. | $16.96M | $3.15 | — |
| MDCX | Medicus Pharma Ltd. | $16.54M | $0.29 | — |
| LEXX | Lexaria Bioscience Corp. | $16.49M | $0.67 | — |
| HCWB | HCW Biologics Inc. | $17.64M | $2.62 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $17.86M | $1.42 | — |
News headlines (Yahoo Finance, 1h cache)
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
2026-04-22 23:54 · Yahoo
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
2026-04-02 20:01 · Yahoo
Exicure, Inc. Reports Full Year 2025 Financial Results
2026-03-25 20:18 · Yahoo
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
2026-02-05 12:00 · Yahoo
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
2026-01-21 12:00 · Yahoo
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
2025-12-08 21:30 · Yahoo
Exicure, Inc. Reports Third Quarter 2025 Financial Results
2025-11-07 21:00 · Yahoo
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
2025-11-03 14:00 · Yahoo
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
2025-10-06 11:00 · Yahoo
Exicure, Inc. Reports Second Quarter 2025 Financial Results
2025-08-08 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.